Achieve life sciences reports statistically significant smoking cessation benefit for cytisinicline in second, confirmatory phase 3 clinical trial

Orca-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo
ACHV Ratings Summary
ACHV Quant Ranking